CDKN1A and nonpapillary renal cell carcinoma: As a conclusion, P21+/MCM2- cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy.